For decades, one of the biggest problems in pain medicine has been surprisingly simple: the strongest medicines often come with the greatest risks. Opioids can make severe pain manageable, but they can also cause dependence, addiction, overdose and troublesome side effects. A new drug called LTG-001 is being developed to see whether powerful pain relief […]

The post A New Way to Stop Pain Without Opioids appeared first on Knowridge Science Report.

Diabetes can slowly damage nerves throughout the body, leaving some people with pain, burning, tingling, or numbness that can become difficult to manage. Now, scientists at UTHealth Houston have developed an experimental treatment that slowed and even reversed this type of nerve damage in mice. The research was published in Science Translational Medicine. Although the […]

The post New Treatment Reverses Nerve Damage in Diabetes appeared first on Knowridge Science Report.

A study has found a possible link between vitamin B12 and inflammation in the body. People with higher levels of vitamin B12 in their blood tended to have lower levels of two important signs of inflammation. The research was published in the Journal of the Science of Food and Agriculture. The findings add to growing […]

The post Vitamin B12 May Help Keep Inflammation in Check appeared first on Knowridge Science Report.

A sweeping new narrative review published in the Journal of Translational Medicine is pulling back the curtain on one of the most overlooked aspects of chronic obstructive pulmonary disease: the devastating toll the disease takes on the body’s muscles, and the crucial — but complicated — role that exercise plays in fighting back. Led by Domenico Di Raimondo and colleagues at the University of Palermo, the review synthesizes decades of mechanistic research into how COPD reshapes both limb and respiratory muscles, how systemic inflammation may or may not be driving that damage, and why rehabilitation remains the most powerful non-drug therapy available despite nagging scientific uncertainties.

COPD has long been framed as a lung disease, defined by airway obstruction, chronic bronchitis, and emphysematous destruction of lung tissue. But clinicians have increasingly recognized that its most disabling features extend far beyond the chest. Patients with COPD frequently suffer from profound muscle wasting, particularly in the quadriceps, and this skeletal muscle dysfunction has emerged as a clinically relevant systemic manifestation of the disease. It contributes directly to the breathlessness that defines daily life for patients, reduces exercise tolerance, erodes quality of life, and — perhaps most tellingly — predicts mortality. A patient’s ability to stand from a chair or climb a flight of stairs, the review argues, may reveal as much about their prognosis as any spirometry reading.

The muscle changes in COPD are not simply the result of disuse, though physical inactivity certainly plays a role. Under the microscope, the peripheral muscles of these patients tell a story of deep biological remodeling. Muscle fibers shift in type, favoring fast-twitch, glycolytic fibers over the oxidative, fatigue-resistant fibers that sustain everyday activity. The oxidative capacity of the muscle falls, undermining the tissue’s ability to generate adenosine triphosphate efficiently and causing lactic acid to accumulate early during exertion — a process that patients experience as overwhelming leg fatigue long before their lungs reach their limits. Capillarization is impaired, reducing the delivery of oxygen and nutrients to working fibers. Mitochondria, the cellular power plants, show structural and functional dysfunction. Oxidative stress, driven by an excess of reactive oxygen species, damages proteins and membranes. And catabolic pathways, including the ubiquitin-proteasome system, are activated, actively breaking down muscle protein faster than the body can rebuild it.

One of the review’s central arguments is that not all muscle in COPD suffers equally, or in the same way. The quadriceps and other limb muscles typically show the destructive changes described above, but the diaphragm follows a different trajectory. The diaphragm in COPD patients is caught in a double bind: it is subject to intrinsic remodeling driven by chronic overload, yet it also works under a severe mechanical disadvantage caused by lung hyperinflation. As the lungs overinflate, the diaphragm flattens, shortens, and loses its mechanical leverage, making every breath more costly. In response, the diaphragm adapts in ways that differ from limb muscles — sometimes showing adaptive, rather than purely destructive, features as it struggles to meet the relentless demands of breathing through compromised lungs. This distinction between limb and respiratory muscle biology, the authors emphasize, matters enormously for understanding why patients with severe airflow obstruction can still have relatively preserved diaphragm function even as their legs waste away.

If the muscle pathology is the crime scene, systemic inflammation has long stood as the prime suspect. Elevated levels of inflammatory mediators such as tumor necrosis factor-alpha, interleukin-6, and C-reactive protein are commonly detected in COPD patients, and these signaling molecules are known to promote muscle protein breakdown, suppress anabolic signaling, and activate catabolic cascades. The review details the molecular routes by which inflammation can sabotage muscle: activation of nuclear factor-kappa B, engagement of the ubiquitin-proteasome system, interference with insulin-like growth factor-1 signaling, and disruption of insulin receptor substrate pathways that normally support muscle growth and glucose uptake. Yet the authors are refreshingly candid about the limits of this story. The true source of systemic inflammation in COPD is still debated — is it the lungs themselves, comorbid conditions, altered gut microbiota, or something else? — and, crucially, the causal contribution of systemic inflammation to muscle loss and dysfunction in COPD patients remains incompletely proven. Inflammation may be an amplifier rather than the sole architect of muscle decline.

Indeed, the review paints muscle wasting in COPD as a multifactorial process in which inflammation is only one ingredient. Ageing naturally erodes muscle mass and regenerative capacity. Multimorbidity — the coexistence of heart failure, chronic kidney disease, and other chronic conditions — compounds the burden. Malnutrition and inadequate caloric intake starve muscle tissue of the building blocks it needs. Hypoxemia, the low blood oxygen characteristic of advanced disease, impairs mitochondrial function and pushes muscle fibers toward glycolytic metabolism. Corticosteroid exposure, a frequent feature of COPD treatment during exacerbations, can further promote protein breakdown and impair anabolic signaling, a process partly mediated by enzymes such as 11 beta-hydroxysteroid dehydrogenase 1 that amplify glucocorticoid activity within muscle tissue. And physical inactivity, both a cause and a consequence of muscle decline, completes a vicious circle in which weakness breeds inactivity, which in turn breeds further weakness. Acute exacerbations of COPD accelerate this cycle dramatically, with each hospitalization potentially stripping away months of hard-won muscle mass and function.

Against this grim mechanistic backdrop, the review delivers its most clinically significant message: exercise training works. Pulmonary rehabilitation, built around structured exercise programs, is firmly supported as a cornerstone of non-pharmacological COPD management. The evidence base shows that exercise training improves muscle function, increases exercise capacity, alleviates symptoms, and restores functional autonomy — the ability of patients to manage their own daily lives. The mechanisms behind these gains are well understood from exercise physiology. Endurance and resistance training stimulate mitochondrial biogenesis through pathways involving peroxisome proliferator-activated receptor-gamma coactivator 1-alpha, the master regulator of oxidative metabolism. Training restores capillary density, shifts muscle fiber types back toward oxidative phenotypes, strengthens the antioxidant defense system against reactive oxygen species, and tips the balance between protein synthesis and breakdown back toward growth. Resistance training in particular offers a direct counterweight to catabolic signaling, mechanically stimulating muscle protein synthesis even in the presence of inflammatory stress.

But the review does not let exercise off the hook without scrutiny. One of its most provocative observations concerns inflammation. If exercise is so beneficial, and if inflammation is a key driver of muscle damage, one might expect training to measurably reduce circulating inflammatory biomarkers such as C-reactive protein, tumor necrosis factor-alpha, or interleukin-6. Yet the current evidence, the authors find, does not consistently demonstrate such a parallel reduction after training programs. Patients get stronger and more functional, but their blood inflammatory profiles often remain stubbornly unchanged. This disconnect raises a fundamental question about how exercise exerts its benefits in COPD: are the improvements driven by chronic adaptations within the cardiac, respiratory, and muscular systems themselves — local remodeling of muscle fibers, capillaries, and mitochondria — or do they also depend on systemic anti-inflammatory effects that clinical trials have so far failed to detect reliably?

The authors frame the resolution of this question as the field’s main unresolved challenge. Beyond the inflammation puzzle, the review identifies a set of pressing practical questions that clinicians and researchers have yet to answer definitively. What is the optimal training modality — endurance, resistance, interval training, or some combination? What intensity and duration produce the greatest and most durable muscle outcomes? And how should rehabilitation be tailored to the phenotype of the individual patient, given that a cachectic, hypoxemic patient with severe hyperinflation may need a fundamentally different program from a breathless but well-nourished patient with preserved muscle mass? The notion of phenotype-specific rehabilitation — matching the training prescription to the patient’s muscle biology, nutritional status, and inflammatory profile — emerges as a promising but still untested frontier.

The review also situates these findings within the broader translational landscape. Many of the molecular pathways it describes — the ubiquitin-proteasome system, the NOD-like receptor pyrin domain-containing protein 3 inflammasome, myostatin-related signaling, and the interplay between hypoxia-inducible factor 1 alpha and mitochondrial function — are potential drug targets. But the authors’ implicit conclusion is that no pharmacological shortcut will soon replace the accumulated, adaptive power of regular physical training. Muscle is plastic tissue, and the review suggests that the therapeutic leverage lies precisely in that plasticity, harnessed through carefully dosed and progressive exercise.

What makes the review timely is its honesty. Rather than inflating the anti-inflammatory credentials of exercise or overselling any single mechanism, it maps the terrain as it actually stands: muscle dysfunction in COPD is real, multifactorial, and deadly serious; exercise is genuinely effective; and the causal chain linking inflammation to muscle loss remains, frustratingly, an open question. For the millions of patients living with COPD worldwide, the practical takeaway is clear. Rehabilitation is not an optional add-on to inhaler therapy — it is a biological intervention that works at the level of the muscle fiber, the mitochondrion, and the capillary, even when the exact systemic chemistry of its benefits remains to be fully explained.

For researchers, the review is a call to arms. Future studies must disentangle the contribution of inflammation from the many other forces eroding muscle in COPD, identify biomarkers that predict who will respond best to which training modality, and design trials that test phenotype-matched rehabilitation strategies rather than one-size-fits-all programs. Until then, the message for clinical practice stands on remarkably firm ground: in COPD, what the lungs cannot fix, the muscles — given the right training — may yet do.

Researchers in Brazil have demonstrated that a hybrid advanced oxidation process can transform pharmaceutical-laden wastewater into an effluent that is dramatically safer for plants, earthworms, onion root cells, and beneficial microorganisms, offering a rigorous ecotoxicological case for reusing treated sewage in agriculture. The study, published in Environmental Science and Pollution Research, addresses a long-standing blind spot in water treatment: proving that a chemically “clean” effluent is also biologically compatible.

Conventional wastewater treatment plants were never designed to strip out recalcitrant organic micropollutants such as pharmaceuticals, and trace amounts routinely slip through into receiving waters. Advanced oxidation processes (AOPs) attack these stubborn compounds by generating highly reactive free radicals that fragment contaminant molecules. But chemical degradation alone does not guarantee safety. As contaminants break down, they spawn transformation products (TPs) that can, in some cases, be as toxic as—or more toxic than—the parent compounds. The research team, led by Lucas Gustavo da Costa and Alam Gustavo Trovó of the Federal University of Uberlândia, together with collaborators at the Oswaldo Cruz Institute, set out to answer a deceptively simple question: does measurable chemical removal of micropollutants actually translate into reduced biological harm?

The centerpiece of their work is the H₂O₂/S₂O₈²⁻/UVC process, a hybrid system that combines hydrogen peroxide and persulfate with short-wave ultraviolet C radiation. UVC photons cleave both oxidants simultaneously, generating hydroxyl radicals (HO•) and sulfate radicals (SO₄•⁻) in the same reaction volume. This dual-radical strategy outperforms systems relying on either oxidant alone, or on peroxymonosulfate (HSO₅⁻), which is costlier and demands more energy for activation. The hybrid route also resists interference from inorganic species commonly found in real effluents, making it an economically attractive candidate for deployment at full-scale treatment plants. The process had already been chemically optimized in the team’s earlier work using multivariate mixture design and rotatable central composite design experiments; the new study is its first integrated biological stress test.

The experiments used real municipal effluent from a wastewater treatment plant in Uberlândia, Minas Gerais, sampled after the plant’s final tertiary treatment stage of coagulation-flocculation with ferric chloride and flotation. The effluent was enriched with three pharmaceuticals representing different therapeutic classes: colchicine (COL, an antimitotic agent), nitazoxanide (NTZ, an antiparasitic), and sulfamethoxazole (SMX, a widely detected antibiotic), each at 325 nmol L⁻¹—equivalent to 130, 100, and 82 micrograms per liter, respectively. That concentration was deliberately chosen as high enough for direct HPLC–DAD analysis without preconcentration, yet low enough to be environmentally representative. Treatment was carried out in an amber glass reactor irradiated by two 8-watt UVC mercury lamps emitting at 254 nm, with a measured irradiance of 4.9 W m⁻². Residual oxidants were neutralized with sodium thiosulfate before any biological testing, ensuring that observed effects could not be attributed to leftover peroxide chemistry.

The ecotoxicological battery spanned multiple trophic levels and levels of biological organization. Oxidative stress was assessed in the earthworm Eisenia andrei by measuring malondialdehyde (MDA), a marker of lipid peroxidation, and protein carbonylation, an irreversible oxidative modification of proteins. Phytotoxicity was evaluated using lettuce (Lactuca sativa) seeds and a growth index combining germination rate and root elongation. Cytotoxicity and genotoxicity were quantified in onion (Allium cepa) root meristems through the mitotic index and the frequency of chromosomal and nuclear aberrations—micronuclei, chromosome breaks, stickiness, bridges, and nuclear buds—across 5,000 cells per sample. Finally, growth inhibition was tested in two environmentally relevant microbes: Azospirillum brasilense, a plant growth-promoting bacterium used in soybean cultivation, and Saccharomyces cerevisiae, a yeast that persists in soils and fermentative niches.

The untreated enriched effluent told a worrying story. It exhibited substantial genotoxicity in onion cells—21%, approaching the 24% seen with the positive control, methyl methanesulfonate—and severe phytotoxicity, with lettuce growth indices far below the 80% threshold that signals absence of toxicity. Even the unspiked effluent itself suppressed lettuce growth, achieving a growth index of only 47%, evidence that bioactive compounds survive conventional treatment. In earthworms, individual aqueous solutions of NTZ and SMX raised MDA levels by 37.2% and 23.5% respectively, while the three-compound mixture increased lipid peroxidation by 38.0%, pointing to additive or synergistic oxidative stress mechanisms involving reactive oxygen species and Fenton-type chemistry within cells.

The picture changed decisively after oxidation. Following 10 minutes of UVC-driven treatment—the point at which 80% chemical degradation had been achieved, matching the minimum removal target proposed in the European Union’s COM(2022)541 directive—genotoxicity fell to 10%, and after 20 minutes, corresponding to the limit of quantification for the parent compounds, it dropped further to 6%, a statistically significant reduction. The plant growth index climbed above 80%, crossing from toxic territory into biocompatibility. The mitotic index in onion cells remained statistically indistinguishable from the deionized-water control (around 39–40% versus 40%), demonstrating that the process generated no cytotoxic byproducts capable of arresting cell division. And crucially for agricultural applications, neither the treated effluent nor its transformation products inhibited growth of A. brasilense or S. cerevisiae.

The mechanistic details are instructive. In the untreated enriched effluent, micronuclei—membrane-bound DNA fragments expelled from the nucleus during flawed cell division—were among the most frequent aberrations, indicating clastogenic and aneugenic damage. Colchicine exposure predictably produced C-metaphase accumulation, a signature of its tubulin-binding, spindle-disrupting mechanism first described in Allium nearly a century ago. SMX depressed the mitotic index and induced chromosomal damage, consistent with prior findings in Vicia faba. NTZ, whose genotoxicity had never before been reported, produced chromosome breaks, stickiness, and nuclear buds. After oxidation, the overall aberration burden fell sharply, particularly micronuclei and stickiness, although a few bridges and polyploid cells persisted even at 20 minutes—a reminder that some transformation products or resistant residuals may linger.

The microbial results came with a subtlety. Reduced A. brasilense growth after treatment initially looked like a red flag, but the team attributes it to depletion of assimilable organic matter, which serves as radical scavenger during oxidation and as a nutrient source afterward—not to toxicity. The negative control likewise grew slowly. This distinction matters because AOPs are designed to mineralize organic carbon, and a nutrient-poorer medium should not be misread as a more toxic one. For S. cerevisiae, no inhibition occurred at any stage of treatment, although NTZ alone significantly depressed yeast optical density, reinforcing the compound’s cell-cycle interference potential even at nanomolar-scale exposures.

The study’s broader significance lies in its methodological stance. By adopting an “effect-driven approach,” the team evaluated the toxicity of whole reaction mixtures without needing to isolate and identify individual transformation products—an impractical task given that many degradation byproducts are not commercially available. Their findings align with a growing consensus that treatment efficacy must be judged not merely by parent-compound removal but by the nature and reactivity of the resulting transformation products. Biochemical biomarkers such as MDA and protein carbonylation detected sublethal disturbances that mortality-based endpoints would have missed entirely, providing early warnings of cellular distress at environmentally relevant concentrations.

One caveat deserves attention: while lipid peroxidation declined after treatment, protein carbonylation rose slightly—1.05-fold above control—suggesting some transformation products may still provoke protein oxidation even as lipid damage subsides. The authors flag this discrepancy and call for future identification of the specific TPs responsible, alongside expanded organism panels, longer-term exposure studies, and pilot-scale validation across different environmental matrices.

The regulatory context sharpens the urgency. The EU’s proposed urban wastewater treatment directive mandates at least 80% removal of specified organic micropollutants and microbiological control for agricultural reuse, yet it conspicuously omits eco-compatibility assessment of the treated water itself. This study supplies exactly that missing dimension, showing that a process satisfying the chemical benchmark also delivers measurable biological benefit—lower genotoxicity, restored plant growth, intact cell division, and unharmed beneficial microbes. As water scarcity intensifies globally and reuse becomes less optional, the Brazilian team’s integrated bioassay framework offers a template for ensuring that the water farmers irrigate with is not merely chemically compliant, but genuinely ecologically safe.

Low back pain is something most people experience at some point in life. Long hours at a desk, repeated lifting, reduced activity and many other factors can contribute, but in most cases doctors cannot identify one specific injury or disease that explains the pain. This common form is called nonspecific low back pain. It accounts […]

The post A Soft Back Belt May Ease Common Low Back Pain appeared first on Knowridge Science Report.